SILVADENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SILVADENE (SILVADENE).
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to microbial DNA and proteins, inhibiting cell wall synthesis and cell division. The sulfadiazine component provides additional bacteriostatic action by competing with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase in folic acid synthesis.
| Metabolism | Silver is minimally absorbed and not metabolized; sulfadiazine is primarily metabolized via hepatic acetylation to N-acetylsulfadiazine, with the parent drug and metabolite excreted renally. |
| Excretion | Silver sulfadiazine applied topically results in minimal systemic absorption. The sulfadiazine component is primarily excreted renally (approximately 70% as unchanged drug and metabolites), with biliary/fecal excretion accounting for a small fraction (<10%). Silver is largely retained in tissues, not excreted. |
| Half-life | The terminal elimination half-life of sulfadiazine is approximately 10-12 hours in patients with normal renal function. Silver has a very long biological half-life (weeks to months) due to tissue deposition. |
| Protein binding | Sulfadiazine is approximately 32-56% bound to plasma proteins (primarily albumin). Silver is extensively bound to tissue proteins. |
| Volume of Distribution | Sulfadiazine: Vd approximately 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid. Silver: Vd is large (up to 10 L/kg) due to extensive tissue binding. |
| Bioavailability | Topical: Systemic bioavailability is low (<10% for sulfadiazine, negligible for silver). Not applicable for IV or oral routes as the drug is exclusively topical. |
| Onset of Action | Topical application: Onset of antimicrobial action is within 1-2 hours as sulfadiazine is released from the cream base and penetrates the wound eschar. |
| Duration of Action | Duration of action: Antimicrobial effect lasts approximately 24 hours, supporting once- or twice-daily application. Reapplication after wound cleansing is recommended. |
Apply a thin layer (approximately 1/16 inch) of 1% cream to the affected area once or twice daily. Use a sterile gloved hand. Reapply as needed to maintain coverage.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment typically required for topical use; however, systemic absorption may occur. In severe renal impairment (CrCl < 30 mL/min), consider monitoring serum sulfadiazine levels and avoid prolonged use. |
| Liver impairment | No specific dose adjustment recommended for topical use; use with caution in severe hepatic impairment due to potential systemic accumulation. |
| Pediatric use | Infants and children: Apply a thin layer (1/16 inch) of 1% cream to the affected area once or twice daily. Avoid use in neonates (< 2 months) due to risk of kernicterus from sulfonamide displacement of bilirubin. |
| Geriatric use | Use same dosing as adults; monitor for local irritation and systemic adverse effects, especially in elderly with impaired renal or hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SILVADENE (SILVADENE).
| Breastfeeding | Silver sulfadiazine is excreted into breast milk in low levels; M/P ratio not established. Sulfonamides may cause kernicterus in jaundiced or G6PD-deficient infants. Use caution, especially in premature infants or those with hyperbilirubinemia. |
| Teratogenic Risk | SILVADENE (silver sulfadiazine) is contraindicated in pregnancy at term and in premature neonates due to risk of kernicterus from sulfonamide displacement of bilirubin. In first and second trimesters, sulfonamides carry theoretical risk of teratogenicity, but human data are insufficient. Avoid use during entire pregnancy unless clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to silver sulfadiazine, sulfonamides, or any component of the formulation. Use on pregnant women approaching term, premature infants, or neonates with hyperbilirubinemia (sulfadiazine displaces bilirubin, increasing kernicterus risk).
| Precautions | May cause leukopenia (usually reversible), fungal superinfection, and delayed wound healing. Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of hemolysis. Avoid prolonged use; monitor for signs of silver toxicity (argyria) with extensive application. Not recommended for use on pregnant women near term or on premature infants due to kernicterus risk from sulfadiazine. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count, renal and hepatic function in mother. Assess neonatal bilirubin levels if exposure near term. |
| Fertility Effects | No clinical data on fertility effects in humans. In animal studies, no impairment of fertility was observed. |